NEXTCELL PHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.235 SEK | -2.76% |
|
-7.84% | -53.04% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
NextCell Pharma AB, formerly Cellaviva AB, is a Sweden-based biopharmaceutical company. The Company is focusing on research and development of stem cell therapies and is also running a tissue establishment and biobank, classified as healthcare provider. NextCell's business concept is to develop and commercialize mesenchymal stem cell products based on the Company's proprietary selection algorithm, primarily for the treatment of autoimmune diabetes, as well as other types of autoimmune diseases.
Calendar
2024-07-24
- Q3 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -53.04% | 4.04M | |
| +22.56% | 46.4B | |
| -1.51% | 41.75B | |
| +48.83% | 41.37B | |
| -3.42% | 29.71B | |
| +10.13% | 26.01B | |
| -20.44% | 19.52B | |
| +26.45% | 12.43B | |
| -0.14% | 12.18B | |
| -0.47% | 12.13B |
- Stock Market
- Equities
- NXTCL Stock
- News NextCell Pharma AB
- NextCell Pharma Chairman to Step Down in May